

Participants With Drug-Related Adverse Events
Weeks 0 to 12
All Participants as Treated

	f			m			Total		
	Placebo	Low Dose	High Dose	Placebo	Low Dose	High Dose	Placebo	Low Dose	High Dose
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Participants in population	53	50	40	33	34	44	86	84	84
with one or more drug-related adverse events	28 (52.8)	41 (82.0)	32 (80.0)	16 (48.5)	32 (94.1)	38 (86.4)	44 (51.2)	73 (86.9)	70 (83.3)
with no drug-related adverse events	25 (47.2)	9 (18.0)	8 (20.0)	17 (51.5)	2 (5.9)	6 (13.6)	42 (48.8)	11 (13.1)	14 (16.7)
Cardiac disorders	4 (7.5)	4 (8.0)	4 (10.0)	2 (6.1)	3 (8.8)	0 (0.0)	6 (7.0)	7 (8.3)	4 (4.8)
Atrial fibrillation	1 (1.9)	0 (0.0)	2 (5.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	0 (0.0)	2 (2.4)
Atrial flutter	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (2.9)	0 (0.0)	0 (0.0)	1 (1.2)	0 (0.0)

Participants With Drug-Related Adverse Events
Weeks 0 to 12
All Participants as Treated

	f						m						Total					
	Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Atrioventricular block first degree	1	(1.9)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)
Atrioventricular block second degree	0	(0.0)	0	(0.0)	0	(0.0)	1	(3.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)
Bradycardia	1	(1.9)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)
Bundle branch block right	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.9)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Cardiac failure congestive	1	(1.9)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)
Myocardial infarction	2	(3.8)	1	(2.0)	1	(2.5)	0	(0.0)	0	(0.0)	0	(0.0)	2	(2.3)	1	(1.2)	1	(1.2)
Palpitations	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.9)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Sinus arrhythmia	0	(0.0)	0	(0.0)	0	(0.0)	1	(3.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)

Participants With Drug-Related Adverse Events
Weeks 0 to 12
All Participants as Treated

	f						m						Total					
	Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Sinus bradycardia	2	(3.8)	1	(2.0)	0	(0.0)	0	(0.0)	1	(2.9)	0	(0.0)	2	(2.3)	2	(2.4)	0	(0.0)
Supraventricular extrasystoles	0	(0.0)	1	(2.0)	1	(2.5)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	1	(1.2)
Ventricular extrasystoles	0	(0.0)	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Wolff-parkinson-white syndrome	0	(0.0)	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Congenital, familial and genetic disorders	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.9)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Ventricular septal defect	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.9)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Ear and labyrinth disorders	0	(0.0)	2	(4.0)	1	(2.5)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	2	(2.4)	1	(1.2)
Tinnitus	0	(0.0)	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Vertigo	0	(0.0)	1	(2.0)	1	(2.5)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	1	(1.2)

Participants With Drug-Related Adverse Events
Weeks 0 to 12
All Participants as Treated

	f						m						Total					
	Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Eye disorders	0	(0.0)	0	(0.0)	1	(2.5)	0	(0.0)	1	(2.9)	0	(0.0)	0	(0.0)	1	(1.2)	1	(1.2)
Vision blurred	0	(0.0)	0	(0.0)	1	(2.5)	0	(0.0)	1	(2.9)	0	(0.0)	0	(0.0)	1	(1.2)	1	(1.2)
Gastrointestinal disorders	1	(1.9)	6	(12.0)	3	(7.5)	3	(9.1)	2	(5.9)	7	(15.9)	4	(4.7)	8	(9.5)	10	(11.9)
Abdominal pain	0	(0.0)	1	(2.0)	1	(2.5)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	1	(1.2)
Diarrhoea	0	(0.0)	3	(6.0)	0	(0.0)	3	(9.1)	0	(0.0)	2	(4.5)	3	(3.5)	3	(3.6)	2	(2.4)
Dyspepsia	1	(1.9)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.9)	0	(0.0)	1	(1.2)	1	(1.2)	0	(0.0)
Gastroesophageal reflux disease	1	(1.9)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)
Nausea	0	(0.0)	2	(4.0)	2	(5.0)	0	(0.0)	1	(2.9)	1	(2.3)	0	(0.0)	3	(3.6)	3	(3.6)
Salivary hypersecretion	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	3	(6.8)	0	(0.0)	0	(0.0)	3	(3.6)
Stomach discomfort	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.3)	0	(0.0)	0	(0.0)	1	(1.2)
Vomiting	0	(0.0)	2	(4.0)	0	(0.0)	0	(0.0)	0	(0.0)	3	(6.8)	0	(0.0)	2	(2.4)	3	(3.6)

Participants With Drug-Related Adverse Events
Weeks 0 to 12
All Participants as Treated

	f						m						Total					
	Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
General disorders and administration site conditions	11	(20.8)	23	(46.0)	17	(42.5)	7	(21.2)	20	(58.8)	18	(40.9)	18	(20.9)	43	(51.2)	35	(41.7)
Application site bleeding	0	(0.0)	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Application site dermatitis	2	(3.8)	5	(10.0)	4	(10.0)	3	(9.1)	4	(11.8)	3	(6.8)	5	(5.8)	9	(10.7)	7	(8.3)
Application site desquamation	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.9)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Application site discharge	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.3)	0	(0.0)	0	(0.0)	1	(1.2)

Participants With Drug-Related Adverse Events
Weeks 0 to 12
All Participants as Treated

	f						m						Total					
	Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Application site discolouration	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.9)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Application site erythema	2	(3.8)	5	(10.0)	5	(12.5)	1	(3.0)	7	(20.6)	10	(22.7)	3	(3.5)	12	(14.3)	15	(17.9)
Application site induration	0	(0.0)	0	(0.0)	0	(0.0)	1	(3.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)
Application site irritation	3	(5.7)	6	(12.0)	5	(12.5)	0	(0.0)	3	(8.8)	4	(9.1)	3	(3.5)	9	(10.7)	9	(10.7)
Application site pain	0	(0.0)	0	(0.0)	2	(5.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	2	(2.4)
Application site perspiration	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	2	(4.5)	0	(0.0)	0	(0.0)	2	(2.4)
Application site pruritus	4	(7.5)	12	(24.0)	10	(25.0)	2	(6.1)	10	(29.4)	12	(27.3)	6	(7.0)	22	(26.2)	22	(26.2)
Application site reaction	0	(0.0)	0	(0.0)	1	(2.5)	1	(3.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	1	(1.2)

Participants With Drug-Related Adverse Events
Weeks 0 to 12
All Participants as Treated

	f						m						Total					
	Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Application site swelling	0	(0.0)	0	(0.0)	1	(2.5)	0	(0.0)	1	(2.9)	1	(2.3)	0	(0.0)	1	(1.2)	2	(2.4)
Application site urticaria	0	(0.0)	0	(0.0)	1	(2.5)	0	(0.0)	2	(5.9)	0	(0.0)	0	(0.0)	2	(2.4)	1	(1.2)
Application site vesicles	0	(0.0)	1	(2.0)	3	(7.5)	1	(3.0)	3	(8.8)	3	(6.8)	1	(1.2)	4	(4.8)	6	(7.1)
Application site warmth	0	(0.0)	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Asthenia	1	(1.9)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)
Chest discomfort	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.3)	0	(0.0)	0	(0.0)	1	(1.2)
Chills	0	(0.0)	0	(0.0)	0	(0.0)	1	(3.0)	1	(2.9)	0	(0.0)	1	(1.2)	1	(1.2)	0	(0.0)
Fatigue	1	(1.9)	1	(2.0)	4	(10.0)	0	(0.0)	1	(2.9)	0	(0.0)	1	(1.2)	2	(2.4)	4	(4.8)
Feeling abnormal	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.3)	0	(0.0)	0	(0.0)	1	(1.2)
Malaise	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.9)	1	(2.3)	0	(0.0)	1	(1.2)	1	(1.2)
Oedema	0	(0.0)	1	(2.0)	0	(0.0)	0	(0.0)	1	(2.9)	0	(0.0)	0	(0.0)	2	(2.4)	0	(0.0)

Participants With Drug-Related Adverse Events
Weeks 0 to 12
All Participants as Treated

	f						m						Total					
	Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Oedema peripheral	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.3)	0	(0.0)	0	(0.0)	1	(1.2)
Pain	0	(0.0)	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.3)	0	(0.0)	1	(1.2)	1	(1.2)
Injury, poisoning and procedural complications	0	(0.0)	2	(4.0)	1	(2.5)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	2	(2.4)	1	(1.2)
Excoriation	0	(0.0)	0	(0.0)	1	(2.5)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)
Fall	0	(0.0)	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Skin laceration	0	(0.0)	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Wound	0	(0.0)	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Investigations	2	(3.8)	2	(4.0)	1	(2.5)	2	(6.1)	0	(0.0)	0	(0.0)	4	(4.7)	2	(2.4)	1	(1.2)
Blood creatine phosphokinase increased	0	(0.0)	0	(0.0)	0	(0.0)	1	(3.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)

Participants With Drug-Related Adverse Events
Weeks 0 to 12
All Participants as Treated

	f						m						Total					
	Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Body temperature increased	0	(0.0)	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Electrocardiogram st segment depression	1	(1.9)	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	1	(1.2)	0	(0.0)
Electrocardiogram t wave inversion	0	(0.0)	0	(0.0)	1	(2.5)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)
Heart rate increased	0	(0.0)	0	(0.0)	0	(0.0)	1	(3.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)
Heart rate irregular	1	(1.9)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)
Metabolism and nutrition disorders	3	(5.7)	0	(0.0)	1	(2.5)	0	(0.0)	0	(0.0)	0	(0.0)	3	(3.5)	0	(0.0)	1	(1.2)
Decreased appetite	1	(1.9)	0	(0.0)	1	(2.5)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	1	(1.2)
Food craving	1	(1.9)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)

Participants With Drug-Related Adverse Events
Weeks 0 to 12
All Participants as Treated

	f						m						Total					
	Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Increased appetite	1	(1.9)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)
Musculoskeletal and connective tissue disorders	0	(0.0)	0	(0.0)	0	(0.0)	1	(3.0)	0	(0.0)	1	(2.3)	1	(1.2)	0	(0.0)	1	(1.2)
Myalgia	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.3)	0	(0.0)	0	(0.0)	1	(1.2)
Shoulder pain	0	(0.0)	0	(0.0)	0	(0.0)	1	(3.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)
Nervous system disorders	3	(5.7)	8	(16.0)	7	(17.5)	2	(6.1)	4	(11.8)	8	(18.2)	5	(5.8)	12	(14.3)	15	(17.9)
Balance disorder	0	(0.0)	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Burning sensation	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	2	(4.5)	0	(0.0)	0	(0.0)	2	(2.4)
Complex partial seizures	0	(0.0)	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)

Participants With Drug-Related Adverse Events
Weeks 0 to 12
All Participants as Treated

	f						m						Total					
	Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Coordination abnormal	0	(0.0)	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Dizziness	1	(1.9)	3	(6.0)	2	(5.0)	1	(3.0)	3	(8.8)	4	(9.1)	2	(2.3)	6	(7.1)	6	(7.1)
Headache	2	(3.8)	0	(0.0)	1	(2.5)	0	(0.0)	1	(2.9)	0	(0.0)	2	(2.3)	1	(1.2)	1	(1.2)
Hypersomnia	0	(0.0)	0	(0.0)	1	(2.5)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)
Lethargy	0	(0.0)	0	(0.0)	1	(2.5)	0	(0.0)	1	(2.9)	0	(0.0)	0	(0.0)	1	(1.2)	1	(1.2)
Paraesthesia oral	0	(0.0)	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Parosmia	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.3)	0	(0.0)	0	(0.0)	1	(1.2)
Somnolence	0	(0.0)	0	(0.0)	0	(0.0)	1	(3.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)
Stupor	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.9)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Syncope	0	(0.0)	4	(8.0)	2	(5.0)	0	(0.0)	0	(0.0)	1	(2.3)	0	(0.0)	4	(4.8)	3	(3.6)
Syncope vasovagal	0	(0.0)	0	(0.0)	1	(2.5)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)
Transient ischaemic attack	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.9)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)

Psychiatric disorders	1 (1.9)	6 (12.0)	1 (2.5)	1 (3.0)	3 (8.8)	4 (9.1)	2 (2.3)	9 (10.7)	5 (6.0)
-----------------------	----------------	-----------------	----------------	----------------	----------------	----------------	----------------	-----------------	----------------

Participants With Drug-Related Adverse Events
Weeks 0 to 12
All Participants as Treated

	f						m						Total					
	Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Agitation	0	(0.0)	2	(4.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	2	(2.4)	0	(0.0)
Anxiety	0	(0.0)	3	(6.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	3	(3.6)	0	(0.0)
Confusional state	0	(0.0)	1	(2.0)	0	(0.0)	1	(3.0)	1	(2.9)	0	(0.0)	1	(1.2)	2	(2.4)	0	(0.0)
Delirium	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.3)	0	(0.0)	0	(0.0)	1	(1.2)
Depressed mood	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.9)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Hallucination, visual	0	(0.0)	0	(0.0)	1	(2.5)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)
Insomnia	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	2	(4.5)	0	(0.0)	0	(0.0)	2	(2.4)
Irritability	1	(1.9)	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	1	(1.2)	0	(0.0)
Libido decreased	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.3)	0	(0.0)	0	(0.0)	1	(1.2)
Listless	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.3)	0	(0.0)	0	(0.0)	1	(1.2)
Restlessness	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.9)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Renal and urinary disorders	0	(0.0)	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.3)	0	(0.0)	1	(1.2)	1	(1.2)

Participants With Drug-Related Adverse Events
Weeks 0 to 12
All Participants as Treated

	f						m						Total					
	Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Enuresis	0	(0.0)	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Micturition urgency	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.3)	0	(0.0)	0	(0.0)	1	(1.2)
Reproductive system and breast disorders	1	(1.9)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)
Pelvic pain	1	(1.9)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)
Respiratory, thoracic and mediastinal disorders	2	(3.8)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	2	(2.3)	0	(0.0)	0	(0.0)
Dyspnoea	1	(1.9)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)
Emphysema	1	(1.9)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)
Skin and subcutaneous tissue disorders	12	(22.6)	21	(42.0)	13	(32.5)	5	(15.2)	18	(52.9)	26	(59.1)	17	(19.8)	39	(46.4)	39	(46.4)

Participants With Drug-Related Adverse Events
Weeks 0 to 12
All Participants as Treated

	f						m						Total					
	Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Blister	0	(0.0)	2	(4.0)	0	(0.0)	0	(0.0)	3	(8.8)	1	(2.3)	0	(0.0)	5	(6.0)	1	(1.2)
Cold sweat	0	(0.0)	0	(0.0)	0	(0.0)	1	(3.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)
Dermatitis contact	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.9)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Erythema	6	(11.3)	7	(14.0)	7	(17.5)	3	(9.1)	6	(17.6)	7	(15.9)	9	(10.5)	13	(15.5)	14	(16.7)
Hyperhidrosis	1	(1.9)	1	(2.0)	2	(5.0)	0	(0.0)	3	(8.8)	6	(13.6)	1	(1.2)	4	(4.8)	8	(9.5)
Pruritus	6	(11.3)	12	(24.0)	11	(27.5)	1	(3.0)	9	(26.5)	15	(34.1)	7	(8.1)	21	(25.0)	26	(31.0)
Pruritus generalised	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.9)	1	(2.3)	0	(0.0)	1	(1.2)	1	(1.2)
Rash	2	(3.8)	6	(12.0)	2	(5.0)	1	(3.0)	5	(14.7)	5	(11.4)	3	(3.5)	11	(13.1)	7	(8.3)
Rash erythematous	0	(0.0)	1	(2.0)	0	(0.0)	0	(0.0)	1	(2.9)	0	(0.0)	0	(0.0)	2	(2.4)	0	(0.0)
Rash maculo-papular	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.3)	0	(0.0)	0	(0.0)	1	(1.2)
Rash papular	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(2.3)	0	(0.0)	0	(0.0)	1	(1.2)
Rash pruritic	0	(0.0)	1	(2.0)	1	(2.5)	0	(0.0)	0	(0.0)	1	(2.3)	0	(0.0)	1	(1.2)	2	(2.4)
Skin	0	(0.0)	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)

Participants With Drug-Related Adverse Events
Weeks 0 to 12
All Participants as Treated

	f						m						Total					
	Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose		Placebo		Low Dose		High Dose	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Skin irritation	2	(3.8)	5	(10.0)	1	(2.5)	0	(0.0)	1	(2.9)	4	(9.1)	2	(2.3)	6	(7.1)	5	(6.0)
Skin ulcer	0	(0.0)	0	(0.0)	0	(0.0)	1	(3.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)
Urticaria	0	(0.0)	0	(0.0)	1	(2.5)	0	(0.0)	1	(2.9)	0	(0.0)	0	(0.0)	1	(1.2)	1	(1.2)
Vascular disorders	0	(0.0)	2	(4.0)	1	(2.5)	1	(3.0)	0	(0.0)	0	(0.0)	1	(1.2)	2	(2.4)	1	(1.2)
Hypertension	0	(0.0)	1	(2.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)
Hypotension	0	(0.0)	1	(2.0)	0	(0.0)	1	(3.0)	0	(0.0)	0	(0.0)	1	(1.2)	1	(1.2)	0	(0.0)
Orthostatic hypotension	0	(0.0)	0	(0.0)	0	(0.0)	1	(3.0)	0	(0.0)	0	(0.0)	1	(1.2)	0	(0.0)	0	(0.0)
Wound haemorrhage	0	(0.0)	0	(0.0)	1	(2.5)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(1.2)
<p>Every participant is counted a single time for each applicable row and column.</p> <p>A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.</p> <p>Adverse event terms are from MedDRA Version 24.0.</p>																		

Source: [CDISCPilot: adam-adsl; adae]